TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NKGen Biotech ( (NKGN) ) has provided an announcement.
On September 4, 2025, NKGen Biotech completed the acquisition of a majority equity stake in NKMax Co., Ltd., a Korean biotechnology company, marking a significant transformation for NKGen. This acquisition grants NKGen full control over NKMax’s global manufacturing infrastructure, intellectual property, and commercialization rights, which is expected to accelerate the clinical development of NKGen’s lead therapeutic candidate, troculeucel, and expand its pipeline of NK cell therapies. The acquisition was supported by approximately $17 million in funding, primarily from AlpineBrook Capital GP I Limited and NKGen’s CEO, Dr. Paul Y. Song. This strategic move positions NKGen as a vertically integrated leader in NK cell therapeutics, with the potential to forge partnerships across Asia and the Middle East, and generate renewed investor interest.
More about NKGen Biotech
NKGen Biotech, Inc. is a clinical-stage biotechnology company based in Santa Ana, California, focused on developing and commercializing innovative autologous and allogeneic natural killer (NK) cell therapeutics.
Average Trading Volume: 87,482
Technical Sentiment Signal: Sell
Current Market Cap: $6.41M
Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page.